PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA

• Guoai Su,
• Kai Hu,
• Xiaoyan Ke,
• Hui Shi,
• Peihao Zheng,
• Fan Yang,
• Shaomei Feng,
• Yuelu Guo,
• Liaxia MA,
• Fei Xue,
• Liu Rui,
• Teng Xu,
• Zhonghua Fu,
• Biping Deng

Affiliations

Guoai Su

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Kai Hu

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Xiaoyan Ke

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Hui Shi

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Peihao Zheng

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Fan Yang

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Shaomei Feng

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Yuelu Guo

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Liaxia MA

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Fei Xue

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Liu Rui

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Teng Xu

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Zhonghua Fu

1 Beijing GoBroad Boren hospital, Department of Hematology and Lymphoma Research Center, Beijing, China

Biping Deng

2 Beijing GoBroad Boren hospital, Cytology Laboratory, Beijing, China